The mission of the Arizona Cancer Center (AZCC) is to prevent and cure cancer. To continue that mission, this application requests a 5-year renewal of the Cancer Center Support Grant (CCSG). The AZCC was founded as a Division of the College of Medicine (COM), University of Arizona (UA) in 1976. It obtained a CCSG in 1978 and was designated a Comprehensive Cancer Center by the NCI in 1990. To accomplish our mission, the basic and translational/clinical and cancer prevention and control research is carried out in six programs, including molecular genetics, cancer metastases and signaling, cancer imaging and technology, gastrointestinal cancer, therapeutic development and cancer prevention and control. These programs are supported by 20 shared services, which help the AZCC (the whole) be greater than the sum of the parts. Since the last renewal, the AZCC team has substantially increased their peer reviewed funding and garnered additional program projects and a GI cancer SPORE. Those accomplishments demonstrate the interdisciplinary activities of the Cancer Center. As we hope the reviewers will see, the team has made considerable progress in their basic and clinical science, including bringing two therapeutic and five prevention agents forward into clinical trials. The renewal outlined in this application is critical to keep us working to accomplish our mission.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Silkensen, Shannon M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Arizona
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Blohm-Mangone, Karen; Burkett, Nichole B; Tahsin, Shekha et al. (2018) Pharmacological TLR4 Antagonism Using Topical Resatorvid Blocks Solar UV-Induced Skin Tumorigenesis in SKH-1 Mice. Cancer Prev Res (Phila) 11:265-278
Tao, Shasha; Rojo de la Vega, Montserrat; Chapman, Eli et al. (2018) The effects of NRF2 modulation on the initiation and progression of chemically and genetically induced lung cancer. Mol Carcinog 57:182-192
Goldenberg, Joshua M; Pagel, Mark D; Cárdenas-Rodríguez, Julio (2018) Characterization of D-maltose as a T2 -exchange contrast agent for dynamic contrast-enhanced MRI. Magn Reson Med 80:1158-1164
Bell, Melanie L; Whitehead, Amy L; Julious, Steven A (2018) Guidance for using pilot studies to inform the design of intervention trials with continuous outcomes. Clin Epidemiol 10:153-157
Russ, Atlantis; Hua, Anh B; Montfort, William R et al. (2018) Blocking ""don't eat me"" signal of CD47-SIRP? in hematological malignancies, an in-depth review. Blood Rev 32:480-489
Berghout, Joanne; Li, Qike; Pouladi, Nima et al. (2018) Single subject transcriptome analysis to identify functionally signed gene set or pathway activity. Pac Symp Biocomput 23:400-411
Kannaiyan, Radhamani; Mahadevan, Daruka (2018) A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther 18:1249-1270
Weinkauf, Craig C; Concha-Moore, Kirsten; Lindner, Jonathan R et al. (2018) Endothelial vascular cell adhesion molecule 1 is a marker for high-risk carotid plaques and target for ultrasound molecular imaging. J Vasc Surg 68:105S-113S
Xie, Shuwei; Reinecke, James B; Farmer, Trey et al. (2018) Vesicular trafficking plays a role in centriole disengagement and duplication. Mol Biol Cell 29:2622-2631
Rice, Photini F S; Ehrichs, Kevin G; Jones, Mykella S et al. (2018) Does Mutated K-RAS Oncogene Attenuate the Effect of Sulindac in Colon Cancer Chemoprevention? Cancer Prev Res (Phila) 11:16-26

Showing the most recent 10 out of 1336 publications